NC525
A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
What's the purpose of the trial?
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
Trial status
Accepting patients
Phase
Phase 1
Enrollment
63
Last Updated
2 weeks ago
Participating Centers
There are 11 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- NC525 is a monoclonal antibody that targets LAIR-1 and is being studied for use in several different cancers.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.